Stage IIIA Breast Cancer Recruiting Phase 2 Trials for Fulvestrant (DB00947)

IndicationStatusPhase
DBCOND0028774 (Stage IIIA Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02860000Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerTreatment
NCT02760030Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryTreatment